Document is current
Any future updates will be listed below
-
Authors
Nachbagauer, Raffael https://orcid.org/0000-0001-5568-5420
Feser, Jodi
Naficy, Abdollah
Bernstein, David I.
Guptill, Jeffrey
Walter, Emmanuel B.
Berlanda-Scorza, Franceso
Stadlbauer, Daniel https://orcid.org/0000-0001-6792-7650
Wilson, Patrick C. https://orcid.org/0000-0002-3537-1245
Aydillo, Teresa
Behzadi, Mohammad Amin
Bhavsar, Disha https://orcid.org/0000-0003-1564-3298
Bliss, Carly
Capuano, Christina
Carreño, Juan Manuel
Chromikova, Veronika
Claeys, Carine
Coughlan, Lynda https://orcid.org/0000-0001-9880-6560
Freyn, Alec W. https://orcid.org/0000-0002-5963-8995
Gast, Christopher
Javier, Andres
Jiang, Kaijun
Mariottini, Chiara
McMahon, Meagan
McNeal, Monica
Solórzano, Alicia
Strohmeier, Shirin
Sun, Weina
Van der Wielen, Marie
Innis, Bruce L.
García-Sastre, Adolfo https://orcid.org/0000-0002-6551-1827
Palese, Peter https://orcid.org/0000-0002-0337-5823
Krammer, Florian https://orcid.org/0000-0003-4121-776X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C00051, HHSN272201400008C, AI128821, AI109946, AI097092, HHSN26620070010C, HHSN272201400008C, AI109946, HHSN26620070010C, HHSN272201400008C, AI109946)
Bill and Melinda Gates Foundation (OPP1084518)
- License Information
-
More Information
Article History
Received: 3 April 2020
Accepted: 2 October 2020
First Online: 7 December 2020
Competing interests
: The Icahn School of Medicine at Mount Sinai (ISMMS) has issued patents and filed patent applications covering the use of chimeric hemagglutinin antigens as vaccines. R.N., A.G.-S., P.P. and F.K. are named as inventors on these patents and applications. The ISMMS and the inventors have received payments as consideration for these rights. The laboratories of A.G.-S., P.P. and F.K. were also engaged in a research program that was funded by GlaxoSmithKline Biologicals SA. M.V.d.W. declares that she is employed by the GSK group of companies and declares no nonfinancial conflicts of interest. C. Claeys was an employee of the GSK group of companies at the time the study was performed. B.L.I. was an employee of the GSK group of companies until 2017 and held shares from this group of companies at the time the study was performed. He is also named as inventor on a patent family regarding influenza virus vaccine constructs filed by the ISMMS and the GSK group of companies. E.B.W. is a coinvestigator for a clinical trial supported by Pfizer. All other authors declare no competing interests.
